CD38 and plasma cell myeloma: Starting from the introduction of the first PIs and IMiDs, the increase in the knowledge of immunological and biological determinants of myeloma evolution,3, 4, 51, 52, 53 enriched the clinical scenario of new schedules and molecules, including the recently approved monoclonal antibodies (the anti‐CD38 daratumumab and isatuximab).